Cullinan Therapeutics reports REZILIENT3 PFS improvement
Cullinan Therapeutics said zipalertinib plus chemotherapy produced a median progression-free survival of 14.5 months versus 8.5 months in the Phase 3 REZILIENT3 trial.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.